Conference Menu

Overview
Register
Download Brochure
Hotel & Travel
Sponsor & Exhibit
Press Pass
Request Information
Archives 



Official Media Partner:

Bio-IT-

Word 


Lead Sponsoring Publications:

Gen 

nature 

The Scientist 

Science AAAS 


Sponsoring Publications:

Drug Discovery News  

Insight Pharma Reports  

 


Web Partner:

Labroots   

Pharmcast  

Biospace  

einnews  

GenomeWeb  

FiercePharma  


Targeting Ocular Disorders - Overview


With the aging of the population, the need for treatments of ocular diseases and disorders has become more important than ever. Increasingly high incidences of age-related macular degeneration (AMD), glaucoma, diabetic retinopathy and ocular inflammatory diseases demand better, more effective and innovative treatments. If we are to maintain the quality of life for this aging population, the preservation of vision is critical. This conference will address targeting of ophthalmic medications and treatments and will provide the latest results in the field, along with novel and emerging targets that hold promise in treating these quality of life threats.


FEATURED PRESENTATION 

Mechanisms of Age-Related Macular Degeneration and Therapeutic Opportunities 

Jennifer LeCouter, Ph.D., Senior Scientist, Immunology Department, Genentech 



EMERGING THERAPIES FOR RETINAL AND MACULAR DISORDERS 

Oral Therapies for Retinal Degeneration: Case Study of ALK-001

Leonide Saad, Ph.D., CEO, Alkeus Pharmaceuticals, Inc.


Wnt Pathway Inhibition for Diabetic Retinopathy

James Larrick, Ph.D., Founder, Managing Scientific Director, CMO, Panorama Research Institute, Wntgen LLC & Velocity Pharmaceutical Development


Systemic Administration of Abeta mAb Reduces Retinal deposition of Abeta and Activated Complement C3 in Age-Related Macular Degeneration Mouse Model

Ian R. Catchpole, Ph.D., Topical BioPharm Discovery Research and Development, Glaxo-Smith Kline


NOVEL PATHWAYS AND STRATEGIES 

A Synthetic Chemically Modified siRNA Targeting Caspase-2 as a Therapeutic Agent for Ocular Neuroprotection

Elena Feinstein, M.D., Ph.D., CSO, Quark Pharmaceuticals


Nanobodies® as Next-Generation Therapeutics for Ocular Applications

Hilde Revets, Ph.D., Senior Research Fellow, Discovery, Ablynx NV


CELL-BASED AND BIOLOGICAL THERAPIES 

AAV-Based Gene Therapy for Genetic Ocular Diseases

Sue Washer, President and CEO, Executive, AGTC


Porous Poly({varepsilon}-caprolactone) Scaffolds for Retinal Pigment Epithelium Transplantation

Magali Saint Geniez, Ph.D., Assistant Scientist, Schepens Eye Research Institute; Assistant Professor, Harvard Medical School



By Series:
By Region:


Conference
& Course Catalog

CHI Catalog 


Short Course DVDs